Fisher Asset Management LLC purchased a new position in Retrophin, Inc. (NASDAQ:RTRX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 75,645 shares of the biopharmaceutical company’s stock, valued at approximately $1,883,000. Fisher Asset Management LLC owned approximately 0.20% of Retrophin at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of RTRX. SG Americas Securities LLC lifted its position in shares of Retrophin by 1.8% in the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 146 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Retrophin by 4.3% in the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 355 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Retrophin in the second quarter worth approximately $246,000. GSA Capital Partners LLP purchased a new stake in shares of Retrophin in the second quarter worth approximately $279,000. Finally, Voya Investment Management LLC lifted its position in shares of Retrophin by 11.8% in the second quarter. Voya Investment Management LLC now owns 17,905 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 1,891 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/10/30/fisher-asset-management-llc-takes-1-88-million-position-in-retrophin-inc-rtrx.html.
Shares of Retrophin, Inc. (NASDAQ:RTRX) opened at 24.41 on Monday. The stock’s market capitalization is $936.98 million. The stock has a 50 day moving average of $24.04 and a 200-day moving average of $20.77. Retrophin, Inc. has a 52-week low of $15.55 and a 52-week high of $25.44.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The business had revenue of $38.80 million for the quarter, compared to the consensus estimate of $37.36 million. During the same quarter last year, the firm earned $0.07 EPS. The company’s revenue for the quarter was up 16.5% on a year-over-year basis. On average, equities research analysts predict that Retrophin, Inc. will post ($1.13) EPS for the current fiscal year.
In other news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total transaction of $31,005.00. Following the transaction, the chief operating officer now owns 13,622 shares in the company, valued at approximately $306,495. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.41% of the company’s stock.
RTRX has been the subject of a number of research analyst reports. ValuEngine raised shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. BidaskClub raised shares of Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research report on Friday, October 6th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Retrophin has an average rating of “Buy” and an average target price of $36.00.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).
What are top analysts saying about Retrophin Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Retrophin Inc. and related companies.